Betsi Cadwaladr University Health Board’s CEO apologised 'for the unacceptable delays' ...

Delays in treating a patient with an aggressive form of prostate cancer more than likely contributed to his disease advancing ...

Is now the time to buy this exciting healthcare stock? The post Exciting clinical news for this ASX healthcare stock earns it a buy recommendation appeared first on The Motley Fool Australia.

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm.

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

First results of the PRIMARY2 randomized phase III trial support consideration of PSMA PET/CT in diagnostic work-up ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.